ImmunoGen, Inc. is a biopharmaceutical company engaged in the development of targeted anticancer therapeutics. The company uses its Targeted Antibody Payload (TAP) technology to develop its own product candidates and outlicenses its technology to other companies for use with their engineered antibodies. ImmunoGen’s lead compound – trastuzumab-DM1 (T-DM1) – is in advanced clinical testing by Genentech and Roche. ImmunoGen is headquartered in Waltham, Massachusetts and its GMP manufacturing facility is in Norwood, Massachusetts. The company has approximately 200 employees in R&D, clinical research, manufacturing, and administrative functions.
CSRHub includes data on Governance, investing, global climate change, environmental policy, ESG ratings, and International Integrated Reporting Council.